Indian pharma faces challenge from Trump tariffs and US regulators

The US is the third largest importer of drugs made in India. But President Trump’s tariffs plan could derail bilateral trade ties.

For decades, India’s export of generic drugs to the US has presented a perfect example of a mutually beneficial trade relationship between the two countries.

The US remains the third largest importer of drugs made in India. The bilateral trade in pharmaceuticals between the two countries is worth around $12.7recent

Free Trial

Register for free to keep reading.

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Weekly podcasts from trusted external experts
  • Fresh compliance and regulatory content every day
Register for free Already a member? Sign in